Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) insider Michael Chi sold 7,500 shares of the stock in a transaction that occurred on Thursday, December 19th. The stock was sold at an average price of $26.00, for a total transaction of $195,000.00. Following the completion of the sale, the insider now owns 193,601 shares in the company, valued at $5,033,626. This represents a 3.73 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Michael Chi also recently made the following trade(s):
- On Tuesday, December 10th, Michael Chi sold 7,259 shares of Hims & Hers Health stock. The stock was sold at an average price of $32.25, for a total transaction of $234,102.75.
- On Monday, December 2nd, Michael Chi sold 2,054 shares of Hims & Hers Health stock. The shares were sold at an average price of $33.56, for a total value of $68,932.24.
- On Friday, October 25th, Michael Chi sold 17,304 shares of Hims & Hers Health stock. The stock was sold at an average price of $22.00, for a total value of $380,688.00.
- On Monday, October 21st, Michael Chi sold 7,500 shares of Hims & Hers Health stock. The shares were sold at an average price of $22.20, for a total value of $166,500.00.
Hims & Hers Health Price Performance
HIMS traded up $1.40 during midday trading on Monday, reaching $27.60. 10,968,314 shares of the company’s stock traded hands, compared to its average volume of 10,082,213. Hims & Hers Health, Inc. has a 52 week low of $8.09 and a 52 week high of $35.02. The firm has a fifty day moving average of $25.78 and a two-hundred day moving average of $21.26. The stock has a market capitalization of $6.03 billion, a price-to-earnings ratio of 62.73 and a beta of 1.25.
Analyst Ratings Changes
Several research firms recently weighed in on HIMS. Canaccord Genuity Group upped their price objective on shares of Hims & Hers Health from $28.00 to $38.00 and gave the stock a “buy” rating in a research report on Monday, December 2nd. Bank of America lowered shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and decreased their price target for the stock from $32.00 to $18.00 in a report on Thursday, November 14th. TD Cowen reiterated a “buy” rating and issued a $28.00 price objective on shares of Hims & Hers Health in a report on Wednesday, November 20th. Morgan Stanley assumed coverage on Hims & Hers Health in a report on Tuesday, December 17th. They set an “overweight” rating and a $42.00 price objective on the stock. Finally, Deutsche Bank Aktiengesellschaft upped their target price on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research note on Wednesday, November 6th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $22.80.
Get Our Latest Research Report on Hims & Hers Health
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of HIMS. Nisa Investment Advisors LLC boosted its position in shares of Hims & Hers Health by 679.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock worth $37,000 after purchasing an additional 1,603 shares in the last quarter. Bank of New York Mellon Corp raised its stake in Hims & Hers Health by 67.5% during the second quarter. Bank of New York Mellon Corp now owns 678,602 shares of the company’s stock valued at $13,701,000 after buying an additional 273,473 shares during the last quarter. State of Michigan Retirement System boosted its holdings in Hims & Hers Health by 177.8% in the second quarter. State of Michigan Retirement System now owns 500,000 shares of the company’s stock worth $10,095,000 after acquiring an additional 320,000 shares in the last quarter. Allspring Global Investments Holdings LLC increased its holdings in shares of Hims & Hers Health by 322.9% during the second quarter. Allspring Global Investments Holdings LLC now owns 52,312 shares of the company’s stock valued at $1,056,000 after acquiring an additional 39,943 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Hims & Hers Health by 33.0% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 27,830 shares of the company’s stock worth $562,000 after purchasing an additional 6,912 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors.
About Hims & Hers Health
Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.
Read More
- Five stocks we like better than Hims & Hers Health
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Dow Jones: A Relevant Benchmark or a Relic of the Past?
- 3 Grocery Stocks That Are Proving They Are Still Essential
- 3 Big-Name Stocks Just Announced Big-Time Dividend Increases
- Why Invest in High-Yield Dividend Stocks?
- Market Overreaction: 2 Stocks to Buy on the Way Down
Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.